United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 31, 2017 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that the U.S. Patent and Trademark's Office (USPTO) Patent Trial and Appeal Board (PTAB) issued a Final Written Decision in connection with the inter partes review (IPR) of United Therapeutics' U.S. Patent No. 8,497,393 (the '393 patent). The PTAB found that all claims of the '393 patent are not patentable. United Therapeutics is evaluating its options, including the possibility of immediately exercising its right of appeal to the U.S. Court of Appeals for the Federal Circuit or first requesting a rehearing before the PTAB. The '393 patent remains valid and enforceable until appeals have been exhausted.

https://yhoo.it/2nJ2VjX